Chromogranin A assay and 131I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma

Journal of Nuclear Medicine

Volumn 42, Issue 7, 2001, Pages 993-997

  D'Herbomez, M ^a   Gouze, V ^a   Huglo, D ^a   Nocaudie, M ^a   Pattou, F ^a   Proye, C ^a   Wemeau J L ^a   Marchandise, X ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

131I metaiodobenzylguanidine scan; Chromogranin A assay; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CHROMOGRANIN A;

ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; SENSITIVITY AND SPECIFICITY; TUMOR SCINTISCANNING; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PARAGANGLIOMA, EXTRA-ADRENAL; PHEOCHROMOCYTOMA; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034960484     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation
2. Secretion of chromogranin A by peptide-producing endocrine neoplasms
3. Phosphorylation of chromogranin A and catecholamine secretion stimulated by elevation of intracellular Ca2+ in cultured bovine adrenal medullary cells
4. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA
5. Structure and function of the chromogranin A gene: Clues to evolution and tissue-specific expression
6. Identification and characterisation of a neuroendocrine-specific 5′-regulatory region of the human chromogranin A gene
7. Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene
8. Chromogranin A: Post-translational modifications in secretory granules
9. Hormone storage vesicle proteins: Transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular
10. Intracellular and extracellular processing of chromogranin A: Determination of cleavage sites
11. Chromogranin A: A multipurpose prohormone?
12. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo
13. Novel autocrine feed-back control of catecholamine release: A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist
14. Desensitization of catecholamine release: The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance
15. Chromogranin A expression in normal and malignant human tissues
16. Characterisation of circulating chromogranin A in human cancer patients
17. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones
18. Chromogranin A: Its clinical value as marker of neuroendocrine turnouts
19. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
20. Plasma chromogranin A in patients with multiple endocrine neoplasia type I
21. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma
22. Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution
23. Chromogranin A storage and secretion: Sensitivity and specificity for the diagnosis of pheochromocytoma
24. Immunoluminometric assay of chromogranin A in serum with commercially available reagents
25. Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel-Lindau disease
26. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma
27. Human pheochromocytoma: Different patterns of catecholamines and chromogranins in the intact tumour, urine and serum in clinically unsuspected cases
28. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones
29. Chromogranin A and chromogranin B are sensitive circulating markers for pheochromocytoma
30. Diagnostic specificity of serum chromogranin A for pheochromocytoma in patients with renal dysfunction
31. Chromogranin A: Storage and release in hypertension
32. Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains
33. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)
34. Library of sequence-specific radioimmunoassays for human chromogranin A
35. Chromogranin A as an early biological marker of a malignant pheochromocytoma recurrence
36. Rapid radioimmunoassay of circulating chromogranin A: In vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure
37. Chromogranin A in uremia: Progressive retention of immunoreactive fragments
38. Iodine-131-MIBG scintigraphy in adults: Interpretation revisited?
39. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: A review of 282 cases
40. Pheochromocytoma in Italy: A multicentric retrospective study